# US 2008/0188431 A1 · Transcytosis of Adeno-Associated Viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188431 A1
- Document ID: US20080188431A1
- Status: Published application
- Kind: A1
- Application number: 11/574,954
- Filed: 2005-09-08
- Published: 2008-08-07
- Earliest claimed: 2004-09-08
- Inventors: John A. Chiorini; Giovanni Di Pasquale
- Web page: https://patentgrep.com/patent/US20080188431A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2750/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods of transcytosing barrier epithelial cells using adeno-associated virus-4 (AAV4), adeno-associated virus-5 (AAV5), adeno-associated virus-7 (AAV7), bovine adeno-associated virus (BAAV), and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid across the barrier epithelia using the AAV4, AAV5, AAV7, and BAAV vectors and particles.

## Claims

### Claim 1

A method of delivering a heterologous nucleic acid across an epithelial barrier comprising delivering to the epithelial barrier an AAV vector comprising the heterologous nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the epithelial cells are in the gut, lung, genitourinary tract, kidney, blood vessels or brain.

### Claim 3 (depends on 1)

The method of claim 1, wherein the epithelial cells are selected from a group consisting of bronchial, alveolar, tracheal or upper airway epithelial cells; absorptive enterocytes; endometrial or urinary epithelial cells; renal collecting duct or proximal tubule epithelial cells; cerebral microvascular endothelial cells; or Choroidal Plexus epithelial cells.

### Claim 4

A method of transcytosing epithelial cells of a human subject comprising administering to the subject an AAV vector comprising a heterologous nucleic acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the epithelial cells are selected from a group consisting of bronchial, alveolar, tracheal or upper airway epithelial cells; absorptive enterocytes; endometrial or urinary epithelial cells; renal collecting duct or proximal tubule epithelial cells; cerebral microvascular endothelial cells; or Choroidal Plexus epithelial cells.

### Claim 6

A method of delivering a heterologous nucleic acid across human airway epithelial cells, comprising delivering to the cells a BAAV vector comprising the nucleic acid.

### Claim 7

A method of delivering a heterologous nucleic acid across human cerebral microvascular endothelial cells, comprising delivering to the cells a BAAV vector comprising the nucleic acid.

### Claim at position 8

8-9. (canceled)

### Claim 10

A method of delivering a heterologous nucleic acid across human enterocytes, comprising delivering to the cells a AAV5 vector comprising the nucleic acid.

### Claim at position 10

11-16. (canceled)

### Claim 17

A method of delivering a heterologous nucleic acid across an epithelial barrier of the lung, comprising delivering to the lung a BAAV vector comprising the nucleic acid.

### Claim 18 (depends on 17)

The method of claim 17, wherein the epithelial barrier comprises human bronchial, alveolar, tracheal or upper airway epithelial cells.

### Claim 19

A method of delivering a heterologous nucleic acid across an epithelial barrier in the brain, comprising delivering to the brain a BAAV vector comprising the nucleic acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the epithelial barrier comprises human cerebral microvascular endothelial cells or Choroidal Plexus epithelial cells of the blood brain barrier.

### Claim at position 15

21-26. (canceled)

### Claim 27

A method of transcytosing lung epithelial cells of a subject comprising contacting the lung epithelial cells of the subject with a BAAV vector comprising a heterologous nucleic acid.

### Claim 28 (depends on 27)

The method of claim 27, wherein the epithelial cells are human bronchial, tracheal, or upper airway epithelial cells.

### Claim 29

A method of transcytosing CNS epithelial cells of a subject comprising contacting the CNS epithelial cells of the subject with a BAAV vector comprising a heterologous nucleic acid.

### Claim 30 (depends on 29)

The method of claim 29, wherein the epithelial cells are human cerebral microvascular endothelial cells or Choroidal Plexus epithelial cells of the blood brain barrier.

### Claim at position 20

31-36. (canceled)

### Claim 37

A method of delivering a heterologous nucleic acid across an epithelial barrier in the gut, comprising delivering to the gut an AAV5 vector comprising the nucleic acid.

### Claim 38 (depends on 37)

The method of claim 37, wherein the epithelial barrier comprises human absorptive enterocytes.

### Claim 39

A method of transcytosing gut epithelial cells of a subject comprising contacting the gut epithelial cells of the subject with an AAV5 vector comprising a heterologous nucleic acid.

### Claim 40 (depends on 39)

The method of claim 39, wherein the epithelial cells are human absorptive enterocytes.

### Claim at position 25

41-68. (canceled)
